Forced nuclear localization of TFEB using AAV9-TFEB(S211A) induces transcription of autophagy-lysosomal genes, enhancing clearance of toxic α-synuclein oligomers. Too early for clinical development; requires validation of autophagy flux biomarkers and non-viral delivery alternatives.
Genetic or pharmacologic NRF2 activation using CDDO-EA or sulforaphane upregulates ARE gene transcription (NQO1, HO-1, GCLM), restoring redox homeostasis impaired across major neurodegenerative diseases. Prioritized as most practical near-term opportunity due to multiple clinical-stage compounds and favorable risk profile.
Convergent vs Divergent Predictions
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
No same-target convergence detected in this selection.
Divergent signals
No direct polarity conflicts detected among the selected hypotheses.
Verdict Summary
4/11
dimensions won
TFEB Nuclear Translocation Clears α-Synu
8/11
dimensions won
NRF2 Activation Provides Neuroprotection
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.65
0.74
Evidence
0.62
0.72
Novelty
0.75
0.55
Feasibility
0.42
0.78
Impact
0.72
0.70
Druggability
0.35
0.88
Safety
0.48
0.62
Competition
0.68
0.65
Data
0.58
0.82
Reproducible
0.55
0.68
KG Connect
0.50
0.50
Score Breakdown
Dimension
TFEB Nuclear Translocation Cle
NRF2 Activation Provides Neuro
Mechanistic
0.650
0.740
Evidence
0.620
0.720
Novelty
0.750
0.550
Feasibility
0.420
0.780
Impact
0.720
0.700
Druggability
0.350
0.880
Safety
0.480
0.620
Competition
0.680
0.650
Data
0.580
0.820
Reproducible
0.550
0.680
KG Connect
0.500
0.500
Evidence
TFEB Nuclear Translocation Clears α-Synuclein via Autophagy-
No evidence citations yet
NRF2 Activation Provides Neuroprotection Across ALS, AD, and
No evidence citations yet
Debate Excerpts
TFEB Nuclear Translocation Clears α-Synuclein via
4 rounds · quality: 0.77
Persona-Theorist
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...
NRF2 Activation Provides Neuroprotection Across AL
4 rounds · quality: 0.77
Persona-Theorist
# Test Preregistration: Therapeutic Hypotheses in Neurodegeneration
## Hypothesis 1: Microglial TREM2 Activation as Therapeutic Target in Alzheimer's Disease
**Title:** TREM2 agonism will reduce amy...
Persona-Skeptic
# Skeptic's Evaluation: Neurodegeneration Therapeutic Hypotheses
## Hypothesis 1: TREM2 Agonism
**Weakest link:** R47H is a *loss-of-function* variant—agonism restores WT signaling, but does pharmaco...
{
"ranked_hypotheses": [
{
"title": "NRF2 Activation Provides Neuroprotection Across ALS, AD, and PD",
"description": "Genetic or pharmacologic NRF2 activation using CDDO-EA or sulfo...